Secarna Pharmaceuticals Demonstrates Therapeutic Activity of LNAplus™ ASO Targeting NLRP3 in Autoinflammatory Diseases

Secarna Pharmaceuticals, a biopharmaceutical company specializing in antisense oligonucleotide (ASO) therapies, has published new preclinical data in The Journal of Immunology. The data demonstrates the potent therapeutic activity of their LNAplus(TM) ASO targeting NLRP3 in debilitating autoinflammatory diseases. NLRP3 is a central component of the inflammasome pathway, which is overactive in ma..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 7.
  • textsms

Upstream Bio Adds Another $200M for Asthma, Allergy Pipeline

Upstream Bio has closed a $200m Series B funding round to enable the advancement of its investigational antibody UPB-101 for mid-stage studies in asthma and chronic rhinosinusitis with nasal polyps. The start-up will also undergo "translational, manufacturing and device development activities" to aid the launch of its Phase III development program. In addition, Thursday’s Series B raise will all..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 9.
  • textsms